Preclinical PET imaging with the novel human antibody (89)Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

BACKGROUND: Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types. Tumorous PD-L1 expression, as assessed by immunohistochemistry (IHC), is an accepted predictive marker of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Marcus P, Makonnen, Sosina, Hickey, Carlos, Arnold, T Cody, Giurleo, Jason T, Tavaré, Richard, Danton, Makenzie, Granados, Christian, Chatterjee, Ishita, Dudgeon, Drew, Retter, Marc W, Ma, Dangshe, Olson, William C, Thurston, Gavin, Kirshner, Jessica R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831708/
https://www.ncbi.nlm.nih.gov/pubmed/33483343
http://dx.doi.org/10.1136/jitc-2020-002025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831708/
https://www.ncbi.nlm.nih.gov/pubmed/33483343
http://dx.doi.org/10.1136/jitc-2020-002025

Ejemplares similares